CSL Behring – Withdrawal of Hizentra® [immune globulin subcutaneous (human)]

- On January 10, 2022 CSL Behring announced an expansion to a patient-level withdrawal, to include two additional lots of Hizentra [immune globulin subcutaneous (human)] due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration. This is an expansion to the withdrawal that was announced on December 30, 2021.

- The withdrawn lots were shipped from CSL Behring between October 5, 2021 and December 15, 2021.

Product Description	NDC	Lot # (Expiration Date)
Hizentra [immune globulin subcutaneous (human)] 20% liquid	44206-0455-10	P100369102 (2/16/2024); P100369103 (2/18/2024)

- Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

- Injection-site reactions and hypersensitivity are a known risk with subcutaneous immune globulin products.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the withdrawn Hizentra.

- Contact CSL Behring Medical Information at **1-800-504-5434** or email **MedinfoNA@cslbehring.com** for more information about the withdrawal.